Liposomes Usher in a New Era for Drug Delivery Research

  • Recently, it is reported that some stunning breakthroughs have been made in gene-editing techniques to treat diversified diseases. Clustered regularly interspaced short palindromic repeat (CRISPR) is such a gene-editing achievement, which has attracted great attention because of its high efficiency. However, the usage of CRISPR is still limited by several barriers, such as the digestion by endonuclease in the serum and reduced cell uptake efficiency due to electrostatic repulsion. To deal with these issues, delivery carrier selection appears to be necessary and the standards for it should be set stringently.


    Under the circumstances, liposomes stand out to be the most suitable gene carriers among several candidates due to their excellence in biodegradability and biocompatibility. Lipid bilayers resembling the cell plasma membrane enable liposomes to integrate a broad variety of drug candidates. Meanwhile, liposomes are capable of prolonging blood circulation time and preventing the enzymatic digestion in the serum. Moreover, many important parameters like the targeting ligands are proved to be adjustable in the liposomal CRISPR delivery system. With considerable merits, liposomes are commonly recognized as the essential supporter of gene editing.


    After conducting more intensive studies on liposomes, researchers are stunned by their prominent properties. Research shows that liposomes are even helpful for drug delivery into the brain. The blood-brain barrier (BBB) functions to protect the brain from harmful substances and naturally prevent the delivery of drugs. Considering the low accessibility of drug delivery, scientists have been beset by the challenges in developing new strategies to treat brain diseases. To fix the puzzle, they attempted to apply liposome-based strategies and received an ideal result. Due to the remarkable biocompatibility of liposomes, lipophilic or hydrophobic drugs are almost completely entrapped in the hydrophobic core of the lipid bilayers of the liposomes.


    Another breakthrough benefits from lipid-based drug delivery systems in vaccines that contribute to the development of mRNA vaccines. Along with the explosion of COVID-19 pandemic, mRNA vaccines surpass other conventional ones due to the advantages of rapid development, large-scale manufacture, and high stability. However, mRNA vaccines also need improvements in transfection efficiency which calls for assistance from lipid components. In the past few years, lipid-based mRNA vaccine delivery has become one of the most appealing and commonly-used strategies.


    All the groundbreaking findings of lipid-based strategies show that liposomes play a vital role both in drug delivery and vaccine development. Therefore, there are massive demands for liposome products and services which require a professional manufacturer. In this case, Creative Biolabs, with first-class technology and an expert team of technicians, is rising to fame in the field. It has established the drug delivery platforms and pre-clinical vaccine platforms to produce liposomal products completely tailored to customers' requirements.


    Owing to the endless efforts on lipid-based drug research from both researchers and technology service companies, we can see a bright future for novel drug development.